Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position with issuance of new patent in the United S
… company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a … event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline …
… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced that Company …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the …
… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … against a key Axiomer patent protecting ADAR-mediated RNAediting Well-capitalized with €139 M, in cash and cash …
… company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer™ RNAediting technology platform and its AX-0810 pipeline program …